Back

The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering therapies: new findings Drug therapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Hideo Tsubata

Kyoto Prefectural University of Medicine, Kyoto (Japan)

8 More presentations in this session

Presentation thumbnail
Rationale and design of the SHASTA-3 and SHASTA-4 studies: randomized, double-blind, placebo-controlled, phase 3 studies of plozasiran in patients with severe hypertriglyceridemia
Doctor D. Gaudet (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
Changes in lipid lowering therapy one year after percutaneous coronary intervention: data from the large contemporary ZON-HR registry
Ms D. Peeters (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis
Doctor D. Mutschlechner (Mistelbach, AT)
Abstract Slides Video
Presentation thumbnail
Association of lipid target achievement and cardiovascular outcomes following statin initiation: a population-based cohort study
Doctor J. Udell (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events
Doctor I. Dykun (Essen, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapies: new findings

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Lower rate of ischemic events with PCSK9 inhibition in patients with atherosclerotic cardiovascular disease but without prior ischemic events
thumbnail
Congress Presentation
Proprotein convertase subtilisin/kexin type 9 levels and the risk of cardiovascular events in statin-treated patients with cardiovascular disease
thumbnail
Congress Presentation
Very short-term effects of single dose of proprotein convertase subtilisin kexin 9 inhibitor therapy before percutaneous coronary intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources